Viking Therapeutics Acquisition Scenario Which Stakeholders Could Benefit Obsession Streaming Release Timing and Market Implications China Confirms 200 Boeing Jet Order Calls Aviation a Key Area for US Cooperation Morgan Stanley Identifies Potential Broader Turnaround at Franklin Resources BEN Jobless Claims Hold at Low Levels Signaling Tight Labor Market Stock Market Mixed as Iran Peace Hopes Lift TechHeavy Indices Dow Fluctuates DVS Q4 2025 Earnings EPS Misses Estimates Significantly as Silver Exploration Continues ARVN Q1 2026 Earnings BetterThanExpected Loss Amid No Revenue Intrusion Inc INTZ Q1 2026 Earnings EPS Misses Estimates Sharply Shares Rise Amid Uncertainty Onity Group Inc ONIT Q1 2026 Earnings EPS Misses Consensus Estimates by Wide Margin LTRN Q1 2026 Earnings NarrowerThanExpected Loss Highlights Cost Control as RD Pipeline Advances DHCNI Q1 2026 Earnings EPS Miss Amid Challenging Operating Environment Vertiv Holdings VRT Reaches 32746 After Modest Gain Nears Key Resistance Level Huntington Bancshares Preferred HBANZ Holds Steady Near Resistance Amid Low Volatility CTBB Edges Higher Qwest Corporation 65 Notes Drift Up in FixedIncome Market Karat Packaging KRT Edges Lower as Stock Holds Above Key Support Level Hennessy Capital Investment Corp VIII Units HCICU Hold Steady at 1004 as Market Awaits Business Combination Progress Tata Motors MD No Need for GST Reduction on FlexFuel Vehicles SPG Q1 2026 Earnings Modest EPS Miss Amid Stable Operational Performance TAVIR Rights Hold Flat at 015 Amid Low Volume and Eventual Catalyst Uncertainty Outset Medical Q1 2026 Earnings EPS Misses Estimates Stock Edges Higher AVIR Q1 2026 Earnings NarrowerthanExpected Loss Boosts Investor Sentiment Dave Busters PLAY Q1 2026 Earnings Massive EPS Miss on Estimated Loss But Stock Rises Amid Strategic Shifts Lesaka Technologies LSAK Q1 2026 Earnings Massive EPS Beat Fails to Lift Stock GAU Q1 2026 Earnings EPS Misses Estimates as Gold Production Holds Steady NeuroOne Medical Technologies NMTC Q1 2026 Earnings EPS Misses Estimates as PreRevenue Biotech Continues to Invest in Development CRVO Q1 2026 Earnings WiderthanExpected Loss as PreClinical Stage Company Reports No Revenue